Search Results for "Xarelto Vs Pradaxa"

11:29 EST 19th December 2014 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa

Columbus, OH (PRWEB) July 27, 2014 The Institute of Safe Medication Practices (ISMP) Found that the number of serious adverse events such as Xarelto bleeding side-effects reported after the use of ...

NICE Clears Pradaxa For DVT, Setting Up Another Clash With Xarelto

NICE has given the thumbs up to Boehringer Ingelheim's Pradaxa in deep vein thrombosis and pulmonary embolism, which means the drug is now set to battle Bayer's Xarelto for market share in this indica...

Portola's New Factor Xa Antidote Could Help Drive Xarelto And Eliquis Sales

By Jon Crowley: Background A few years ago, three new-generation anticoagulants were released in an attempt to improve upon and replace Coumadin. First released was Pradaxa, a direct thrombin inhibi...

Pradaxa MDL Court Orders Establishment of Qualified Settlement Fund, Notes Rottenstein Law Group LLP

The firm currently represents patients who allege that they have suffered serious side effects from use of anticoagulants Pradaxa and Xarelto. Rockville Centre, NY (PRWEB) August 19, 2014 The Rottens...

Pradaxa Available in the UK for DVT, PE

Boehringer Ingelheim has announced that Pradaxa will be commercially available in the UK for the treatment of DVT and PE

Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use

Columbus, OH (PRWEB) November 22, 2014 A Xarelto lawsuit has been filed on behalf of a 72-year-old New York woman who is seeking $10 million in damages from the makers and marketers of the Xarelto...

Xarelto Lawsuit News: The Rottenstein Law Group Comments on New Study that Shows Xarelto® Surpassing Pradaxa in the Number of Reported Injuries

The firm currently represents patients who allege that they have suffered serious side effects from use of Xarelto. Rockville Centre, NY (PRWEB) June 26, 2014 The Rottenstein Law Group LLP, a nationa...

BI Kicks Off Pradaxa First Ablation Trial

Boehringer Ingelheim announced the initiation of a new international study of Pradaxa (dabigatran etexilate mesylate).

Matching PubMed Articles

Perioperative management and therapy of bleeding complications.

The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophyla...

Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

A sensitive and accurate liquid chromatography method with mass spectrometry detection was developed and validated for the quantification of dabigatran (Pradaxa(®)) and rivaroxaban (Xarelto(®)). (13...


To report the first known case of spontaneous choroidals in association with a patient on dabigatran etexilate.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement